Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases

Carla Felice, Daniela Pugliese, Luigi Giovanni Papparella, Fabrizio Pizzolante, Eugenia Onori, Antonio Gasbarrini, Gian Lodovico Rapaccini, Luisa Guidi, Alessandro Armuzzi

Research output: Contribution to journalReview article

Abstract

Introduction: Spondyloarthritis (SpA) is the most common extra-intestinal manifestation in patients with inflammatory bowel diseases (IBD). Articular disorders may also appear as ‘paradoxical’ effects during biologic therapy with anti-tumor necrosis factor (TNF). Areas covered: In this narrative review, we report the current knowledge about the pathogenesis, the diagnosis and the therapeutic management of articular diseases occurring in patients with IBD. Expert commentary: Evidence-based recommendations for the management of IBD-associated SpA and paradoxical arthritis are lacking. Then, collaboration between gastroenterologists and rheumatologists is mandatory to guarantee the best outcomes for these patients, from a prompt diagnosis to an appropriate therapeutic strategy. Among therapies currently available, steroids, sulfasalazine, methotrexate and anti-TNFs are recommended for both gastrointestinal and articular diseases, whereas non-steroidal anti-inflammatory drugs (NSAIDs) and etanercept are contraindicated in IBD. Thiopurines are not effective for the treatment of articular symptoms. Several agents have been recently introduced for the treatment of IBD, such as vedolizumab, a gut-selective anti-α4β7integrin, and ustekinumab, an anti-interleukin 12/23. Their effects on SpA still need to be clarified; however, the possible contemporary administration of biologics with different molecular targets is becoming an intriguing option to cover multiple inflammatory manifestations in the same patient and is worthy of further investigation.

Original languageEnglish
Pages (from-to)751-759
Number of pages9
JournalExpert Review of Clinical Immunology
Volume14
Issue number9
DOIs
Publication statusPublished - Sep 2 2018

Fingerprint

Inflammatory Bowel Diseases
Joints
Interleukin-23
Therapeutics
Sulfasalazine
Biological Therapy
Gastrointestinal Diseases
Interleukin-12
Disease Management
Biological Products
Methotrexate
Arthritis
Anti-Inflammatory Agents
Tumor Necrosis Factor-alpha
Steroids
Pharmaceutical Preparations

Keywords

  • Extra-intestinal manifestation
  • inflammatory bowel disease
  • multidisciplinary management
  • paradoxical arthritis
  • spondyloarthritis
  • therapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases. / Felice, Carla; Pugliese, Daniela; Papparella, Luigi Giovanni; Pizzolante, Fabrizio; Onori, Eugenia; Gasbarrini, Antonio; Rapaccini, Gian Lodovico; Guidi, Luisa; Armuzzi, Alessandro.

In: Expert Review of Clinical Immunology, Vol. 14, No. 9, 02.09.2018, p. 751-759.

Research output: Contribution to journalReview article

Felice, Carla ; Pugliese, Daniela ; Papparella, Luigi Giovanni ; Pizzolante, Fabrizio ; Onori, Eugenia ; Gasbarrini, Antonio ; Rapaccini, Gian Lodovico ; Guidi, Luisa ; Armuzzi, Alessandro. / Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases. In: Expert Review of Clinical Immunology. 2018 ; Vol. 14, No. 9. pp. 751-759.
@article{54d23e1ea62d4275b3348ef178109a17,
title = "Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases",
abstract = "Introduction: Spondyloarthritis (SpA) is the most common extra-intestinal manifestation in patients with inflammatory bowel diseases (IBD). Articular disorders may also appear as ‘paradoxical’ effects during biologic therapy with anti-tumor necrosis factor (TNF). Areas covered: In this narrative review, we report the current knowledge about the pathogenesis, the diagnosis and the therapeutic management of articular diseases occurring in patients with IBD. Expert commentary: Evidence-based recommendations for the management of IBD-associated SpA and paradoxical arthritis are lacking. Then, collaboration between gastroenterologists and rheumatologists is mandatory to guarantee the best outcomes for these patients, from a prompt diagnosis to an appropriate therapeutic strategy. Among therapies currently available, steroids, sulfasalazine, methotrexate and anti-TNFs are recommended for both gastrointestinal and articular diseases, whereas non-steroidal anti-inflammatory drugs (NSAIDs) and etanercept are contraindicated in IBD. Thiopurines are not effective for the treatment of articular symptoms. Several agents have been recently introduced for the treatment of IBD, such as vedolizumab, a gut-selective anti-α4β7integrin, and ustekinumab, an anti-interleukin 12/23. Their effects on SpA still need to be clarified; however, the possible contemporary administration of biologics with different molecular targets is becoming an intriguing option to cover multiple inflammatory manifestations in the same patient and is worthy of further investigation.",
keywords = "Extra-intestinal manifestation, inflammatory bowel disease, multidisciplinary management, paradoxical arthritis, spondyloarthritis, therapy",
author = "Carla Felice and Daniela Pugliese and Papparella, {Luigi Giovanni} and Fabrizio Pizzolante and Eugenia Onori and Antonio Gasbarrini and Rapaccini, {Gian Lodovico} and Luisa Guidi and Alessandro Armuzzi",
year = "2018",
month = "9",
day = "2",
doi = "10.1080/1744666X.2018.1513329",
language = "English",
volume = "14",
pages = "751--759",
journal = "Expert Review of Clinical Immunology",
issn = "1744-666X",
publisher = "Expert Reviews Ltd.",
number = "9",

}

TY - JOUR

T1 - Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases

AU - Felice, Carla

AU - Pugliese, Daniela

AU - Papparella, Luigi Giovanni

AU - Pizzolante, Fabrizio

AU - Onori, Eugenia

AU - Gasbarrini, Antonio

AU - Rapaccini, Gian Lodovico

AU - Guidi, Luisa

AU - Armuzzi, Alessandro

PY - 2018/9/2

Y1 - 2018/9/2

N2 - Introduction: Spondyloarthritis (SpA) is the most common extra-intestinal manifestation in patients with inflammatory bowel diseases (IBD). Articular disorders may also appear as ‘paradoxical’ effects during biologic therapy with anti-tumor necrosis factor (TNF). Areas covered: In this narrative review, we report the current knowledge about the pathogenesis, the diagnosis and the therapeutic management of articular diseases occurring in patients with IBD. Expert commentary: Evidence-based recommendations for the management of IBD-associated SpA and paradoxical arthritis are lacking. Then, collaboration between gastroenterologists and rheumatologists is mandatory to guarantee the best outcomes for these patients, from a prompt diagnosis to an appropriate therapeutic strategy. Among therapies currently available, steroids, sulfasalazine, methotrexate and anti-TNFs are recommended for both gastrointestinal and articular diseases, whereas non-steroidal anti-inflammatory drugs (NSAIDs) and etanercept are contraindicated in IBD. Thiopurines are not effective for the treatment of articular symptoms. Several agents have been recently introduced for the treatment of IBD, such as vedolizumab, a gut-selective anti-α4β7integrin, and ustekinumab, an anti-interleukin 12/23. Their effects on SpA still need to be clarified; however, the possible contemporary administration of biologics with different molecular targets is becoming an intriguing option to cover multiple inflammatory manifestations in the same patient and is worthy of further investigation.

AB - Introduction: Spondyloarthritis (SpA) is the most common extra-intestinal manifestation in patients with inflammatory bowel diseases (IBD). Articular disorders may also appear as ‘paradoxical’ effects during biologic therapy with anti-tumor necrosis factor (TNF). Areas covered: In this narrative review, we report the current knowledge about the pathogenesis, the diagnosis and the therapeutic management of articular diseases occurring in patients with IBD. Expert commentary: Evidence-based recommendations for the management of IBD-associated SpA and paradoxical arthritis are lacking. Then, collaboration between gastroenterologists and rheumatologists is mandatory to guarantee the best outcomes for these patients, from a prompt diagnosis to an appropriate therapeutic strategy. Among therapies currently available, steroids, sulfasalazine, methotrexate and anti-TNFs are recommended for both gastrointestinal and articular diseases, whereas non-steroidal anti-inflammatory drugs (NSAIDs) and etanercept are contraindicated in IBD. Thiopurines are not effective for the treatment of articular symptoms. Several agents have been recently introduced for the treatment of IBD, such as vedolizumab, a gut-selective anti-α4β7integrin, and ustekinumab, an anti-interleukin 12/23. Their effects on SpA still need to be clarified; however, the possible contemporary administration of biologics with different molecular targets is becoming an intriguing option to cover multiple inflammatory manifestations in the same patient and is worthy of further investigation.

KW - Extra-intestinal manifestation

KW - inflammatory bowel disease

KW - multidisciplinary management

KW - paradoxical arthritis

KW - spondyloarthritis

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=85053840133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053840133&partnerID=8YFLogxK

U2 - 10.1080/1744666X.2018.1513329

DO - 10.1080/1744666X.2018.1513329

M3 - Review article

VL - 14

SP - 751

EP - 759

JO - Expert Review of Clinical Immunology

JF - Expert Review of Clinical Immunology

SN - 1744-666X

IS - 9

ER -